department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Vanflyta · pharmadog

pharmadog
drugs
Vanflyta

drug

patient view →

quizartinib dihydrochloride

Marketedupdated 2mo ago

by Daiichi Sankyo Co Ltd

Approved

community read0 votes

all catalysts(3)

approval · 3

VANFLYTA (QUIZARTINIB DIHYDROCHLORIDE) — FDA approval

quizartinib dihydrochloride

VANFLYTA (QUIZARTINIB DIHYDROCHLORIDE) — FDA approval

quizartinib dihydrochloride

VANFLYTA (QUIZARTINIB DIHYDROCHLORIDE) — FDA approval

quizartinib dihydrochloride

News(0)

no news has mentioned this drug yet

brand

Vanflyta

generic

quizartinib dihydrochloride

indication

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)

phase

marketed

Data sources

openFDA · ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Patent cliff

source: FDA Orange Book

first barrier falls

Mar 16, 2027

252 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (22)

Sep 30, 2033formulationUS 9675549
Sep 30, 2033formulationUS 9675549
Feb 26, 2031method-of-use (U-3661)US 83576904.6y
Feb 26, 2031method-of-use (U-3661)US 83576904.6y
May 14, 2030method-of-use (U-3661)US 95550403.9y
May 14, 2030method-of-use (U-3661)US 95550403.9y
Mar 23, 2030method-of-use (U-3661)US 88362183.7y
Mar 23, 2030method-of-use (U-3661)US 88362183.7y
Aug 15, 2029formulationUS 79685433.1y
Aug 15, 2029formulationUS 79685433.1y
Aug 15, 2029formulationUS 88657103.1y
Aug 15, 2029formulationUS 88657103.1y
Sep 26, 2028compositionUS 78206572.2y
Sep 26, 2028compositionUS 78206572.2y
Mar 16, 2027method-of-use (U-3661)US 8129374252d
Mar 16, 2027method-of-use (U-3661)US 8129374252d
Mar 16, 2027formulationUS 8557810252d
Mar 16, 2027formulationUS 8557810252d
Mar 16, 2027compositionUS 8883783252d
Mar 16, 2027compositionUS 8883783252d
Mar 16, 2027method-of-use (U-3661)US 9585892252d
Mar 16, 2027method-of-use (U-3661)US 9585892252d

FDA exclusivities (4)

Jul 20, 2030ODE-437Orphan Drug (7y)4.0y
Jul 20, 2030ODE-437Orphan Drug (7y)4.0y
Jul 20, 2028NCENew Chemical Entity (5y)2.0y
Jul 20, 2028NCENew Chemical Entity (5y)2.0y

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 3

tagApproval12 co-mentions · 3 sources
drugVANFLYTA12 co-mentions · 3 sources
tagSmall Molecule6 co-mentions · 3 sources